TIDMNSCI
NetScientific PLC
28 January 2022
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Biotech Announces Preclinical Data for PDS0202 Universal
Influenza Vaccine
London, UK - 28 January 2022 - NetScientific plc (AIM: NSCI),
the international life sciences and sustainability technology
investment and commercialisation Group, announces that its
portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB)
("PDS"), announced yesterday preclinical data for its universal flu
vaccine, which was shown to be effective against multiple strains
of the influenza virus.
PDS Biotechnology is developing a new generation of flu vaccines
with the potential to provide long-lasting, and broad protection
against multiple strains of the virus. PDS believes that the
successful development of a universal flu vaccine could eliminate
the need to create a vaccine to protect against each year's
predicted variants. According to the World Health Organization,
influenza causes 3 to 5 million cases and approximately 290,000 to
650,000 deaths each year.
PDS0202 combines PDS Biotech's proprietary Infectimune(TM)
technology with proprietary COBRA (Computationally Optimized
Broadly Reactive Antigens) designed by renowned influenza expert
Dr. Ted Ross. PDS Biotech announced an agreement with the
University of Georgia to license the COBRA antigens.
The NIAID-sponsored preclinical work was performed by Dr. Jerold
Woodward at the University of Kentucky College of Medicine and Dr.
Ted Ross at the University of Georgia, in collaboration with PDS
Biotech. The studies demonstrated the ability of PDS0202 to promote
robust induction of broadly neutralizing influenza-specific
antibodies, flu-specific CD4 (helper) and CD8 (killer) T-cells, as
well as long-lasting memory T-cells. This well characterized and
robust immune response to the COBRA antigens suggests strong
potential for broad and long-term protection against multiple
strains of influenza.
Dr. Lauren V. Wood, MD, Chief Medical Officer of PDS Biotech
said: "We are excited by the highly promising preclinical results
generated in collaboration with Drs. Woodward and Ross. The COBRA
antigens provide an innovative approach to generating broadly
effective immune responses against influenza, which when combined
with our Infectimune(TM) platform may provide effective
neutralization and protection against infection. The data suggests
that PDS0202, has the potential to overcome the well documented
limitations faced in developing a universal influenza vaccine."
Ted Ross, Ph.D., Professor and Director of the Center for
Vaccines and Immunology, University of Georgia, added: "The
preclinical results show the potential for PDS0202 to be effective
in preventing viral invasion of the lungs by multiple strains of
the influenza virus. We look forward to seeing the PDS0202-COBRA
vaccine in future human trials."
Ilian Iliev, CEO of NetScientific, commented: "This preclinical
data demonstrates the indicative strength of the PDS0202 vaccine,
aiming to provide a highly-scalable and robust, universal vaccine
for a widespread global issue. The data highlights the strength of
PDS' innovative research, and we look forward to seeing what is in
store as it progresses through clinical trials."
The full text of the announcement from PDS Biotechnology is
reproduced below and is available online here:
https://pdsbiotech.com/investors/news-center/press-releases/press-releases1/118-2022-news/588-iotechnnouncesreclinicalatafor0202niversa20220127
###
FLORHAM PARK, N.J., Jan. 27, 2022 (GLOBE NEWSWIRE) -- PDS
Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company's proprietary
Versamune(R) and Infectimune(TM) T-cell activating technologies,
today announced preclinical data for its universal flu vaccine,
which was shown to be effective against multiple strains of the
influenza virus.
Due to the existence of multiple strains of flu, a new seasonal
flu vaccination is usually developed to provide protection against
the strains predicted to be prevalent in an upcoming flu season. As
a result, the protective efficacy of the current vaccines varies
widely from season to season. PDS Biotechnology is developing a new
generation of flu vaccines with the potential to provide
long-lasting, and broad protection against multiple strains of the
virus. We believe that the successful development of a universal
flu vaccine could eliminate the need to create a vaccine to protect
against each year's predicted variants. According to the World
Health Organization, influenza causes 3 to 5 million cases and
approximately 290,000 to 650,000 deaths each year.
PDS0202 combines PDS Biotech's proprietary Infectimune(TM)
technology with proprietary COBRA (Computationally Optimized
Broadly Reactive Antigens) designed by renowned influenza expert
Dr. Ted Ross. PDS Biotech announced an agreement with the
University of Georgia to license the COBRA antigens.
The NIAID-sponsored preclinical work was performed by Dr. Jerold
Woodward at the University of Kentucky College of Medicine and Dr.
Ted Ross at the University of Georgia, in collaboration with PDS
Biotech. Dr. Ted Ross is Principal Investigator at the National
Institute of Allergy and Infectious Diseases (NIAID) Collaborative
Influenza Vaccine Innovation Center (CIVICs) located at the
University of Georgia. The studies demonstrated the ability of
PDS0202 to promote robust induction of broadly neutralizing
influenza -specific antibodies, flu-specific CD4 (helper) and CD8
(killer) T-cells, as well as long-lasting memory T-cells. This well
characterized and robust immune response to the COBRA antigens
suggests strong potential for broad and long-term protection
against multiple strains of influenza.
"We are excited by the highly promising preclinical results
generated in collaboration with Drs. Woodward and Ross," said Dr.
Lauren V. Wood, MD, Chief Medical Officer of PDS Biotech. "The
COBRA antigens provide an innovative approach to generating broadly
effective immune responses against influenza, which when combined
with our Infectimune(TM) platform may provide effective
neutralization and protection against infection. The data suggest
that PDS0202, has the potential to overcome the well documented
limitations faced in developing a universal influenza vaccine."
"The novel mechanisms by which the PDS Biotech-patented lipids
activate critical immunological pathways may allow us to develop a
new generation of vaccines that could be more effective in
protecting us from infectious pathogens like influenza and
Covid-19," stated Jerold Woodward, Ph.D., Professor of Immunology
at the University of Kentucky, College of Medicine.
"The preclinical results show the potential for PDS0202 to be
effective in preventing viral invasion of the lungs by multiple
strains of the influenza virus," stated Ted Ross, Ph.D., Professor,
and Director of the Center for Vaccines and Immunology, University
of Georgia. "We look forward to seeing the PDS0202-COBRA vaccine in
future human trials."
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing
a growing pipeline of cancer and infectious disease immunotherapies
based on the Company's proprietary Versamune(R) and Infectimune(TM)
T-cell activating technology platforms.
Our Versamune(R)-based products have demonstrated the potential
to overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune(R) and disease-specific antigens, designed to train
the immune system to better recognize diseased cells and
effectively attack and destroy them. The Company's pipeline
products address various cancers including HPV16-associated cancers
(anal, cervical, head and neck, penile, vaginal, vulvar) and
breast, colon, lung, prostate and ovarian cancers.
Our Infectimune(TM)-based vaccines have demonstrated the
potential to induce not only robust and durable neutralizing
antibody responses, but also powerful T-cell responses including
long-lasting memory T-cell responses. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Forward Looking Statements
This communication contains forward-looking statements
(including within the meaning of Section 21E of the United States
Securities Exchange Act of 1934, as amended, and Section 27A of the
United States Securities Act of 1933, as amended) concerning PDS
Biotechnology Corporation (the "Company") and other matters. These
statements may discuss goals, intentions and expectations as to
future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the Company's
management, as well as assumptions made by, and information
currently available to, management. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as "may," "will," "should," "would," "expect,"
"anticipate," "plan," "likely," "believe," "estimate," "project,"
"intend," "forecast," "guidance", "outlook" and other similar
expressions among others. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the Company's ability to protect its
intellectual property rights; the Company's anticipated capital
requirements, including the Company's anticipated cash runway and
the Company's current expectations regarding its plans for future
equity financings; the Company's dependence on additional financing
to fund its operations and complete the development and
commercialization of its
product candidates, and the risks that raising such additional
capital may restrict the Company's operations or require the
Company to relinquish rights to the Company's technologies or
product candidates; the Company's limited operating history in the
Company's current line of business, which makes it difficult to
evaluate the Company's prospects, the Company's business plan or
the likelihood of the Company's successful implementation of such
business plan; the timing for the Company or its partners to
initiate the planned clinical trials for PDS0101, PDS0203 and other
Versamune(R) based products; the future success of such trials; the
successful implementation of the Company's research and development
programs and collaborations, including any collaboration studies
concerning PDS0101, PDS0203 and other Versamune(R) based products
and the Company's interpretation of the results and findings of
such programs and collaborations and whether such results are
sufficient to support the future success of the Company's product
candidates; the success, timing and cost of the Company's ongoing
clinical trials and anticipated clinical trials for the Company's
current product candidates, including statements regarding the
timing of initiation, pace of enrollment and completion of the
trials (including our ability to fully fund our disclosed clinical
trials, which assumes no material changes to our currently
projected expenses), futility analyses, presentations at
conferences and data reported in an abstract, and receipt of
interim results (including, without limitation, any preclinical
results or data), which are not necessarily indicative of the final
results of the Company's ongoing clinical trials; any Company
statements about its understanding of product candidates mechanisms
of action and interpretation of preclinical and early clinical
results from its clinical development programs and any
collaboration studies; the acceptance by the market of the
Company's product candidates, if approved; the timing of and the
Company's ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, the Company's product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company's control, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to COVID-19. The foregoing review of
important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and
elsewhere, including the risk factors included in the Company's
annual and periodic reports filed with the SEC. The forward-looking
statements are made only as of the date of this press release and,
except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
###
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR +44 (0)20 7933 8780 or netscientific@walbrookpr.com
Nick Rome / Nicholas Johnson / Paul 07748 325 236 / 07884 664 686 / 07980
McManus 541 893
About NetScientific
NetScientific plc (AIM: NSCI) is a holding company, that invests
in, develops, commercialises and realises shareholder value in life
sciences/healthcare, sustainability and technology companies, which
offer significant growth potential predominately in the UK and USA,
as well as globally.
With the acquisition of EMV Capital in August 2020, the Group
doubled its portfolio from 8 to 17 companies, either through direct
subsidiary, balance sheet investment or capital under advisory,
varying from start-up private companies to publicly listed
equities.
NetScientific delivers shareholder returns through a proactive
and hands-on management approach to their portfolio companies;
identifying, investing in, and helping to build game-changing
companies. The Group targets value inflection points and the
release of value through partial or full exits from trade sales,
public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing
attractive expansion prospects.
NSCI can deploy a capital-light investment structure; utilising
the power of the PLC Brand, and the NetScientific balance sheet to
anchor future investments and achieve a multiplier effect by
attracting 3rd party investment for the portfolio companies.
NetScientific is headquartered in London, United Kingdom, and
was admitted to trading on AIM, a market operated by the London
Stock Exchange, in 2013 (website: netscientific.net ).
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZGZMRRZGZZG
(END) Dow Jones Newswires
January 28, 2022 03:45 ET (08:45 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024